Recordati acquires Herbacos-Bofarma
Giovanni Recordati, chairman and CEO of Recordati, said: “The acquisition of Herbacos-Bofarma represents a further step in our strategy of building a direct presence in Central and Eastern
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
This expands the commercialization agreement between Intercell and Novartis to these territories, which previously were not covered by the initial marketing and distribution agreement for Intercell’s Japanese encephalitis